Valeant shares sink anew on report it may restate earnings

Shares of Valeant Pharmaceuticals plunged anew after-hours on Monday after the Wall Street Journal reported that the drugmaker may restate earnings after an internal review. “Valeant … likely needs to restate some of its previous financial results based on the findings of an internal investigation into its business,” the Journal said on its website. 
In regular NYSE trading on Monday, Valeant shares were down $9.07 to $75.92&nb